Table 1 Participants' baseline characteristics
| Â | Placebo N = 14 | Piroxicam N = 14 |
|---|---|---|
General characteristics | Â | Â |
Age, years | 82.5 (79.5-86.5) | 85.0 (76.8-91.0) |
Gender, number (%) female | 10 (71.4%) | 9 (64.3%) |
BMI, kg/m2 | 23.6 (18.3-26.3) | 26.2 (20.1-28.2) |
   Proportion BMI < 20 | 4 (28.6%) | 2 (14.3%) |
   Proportion BMI > 25 | 5 (35.7%) | 8 (57.1%) |
bADL, 24 point Katz scale | 18.0 (10.3-20.3) | 12.0 (9.5-19.5) |
iADL, 7 point Lawton scale | 1.5 (0.3-3.5) | 2.0 (1.0-4.0) |
EMS, 20 point scale | 5.5 (1.0-8.0) | 2.5 (0.0-8.5) |
Type of infection & comorbidity | Â | Â |
   - Respiratory, number | 8 (57.1%) | 6 (42.9%) |
   - Urinary, number | 1 (7.1%) | 4 (28.6%) |
   - Gastro-intestinal, number | 3 (21.4%) | 1 (7.1%) |
   Other, number | 2 (14.3%) | 3 (21.4%) |
Number of diagnoses | 7.0 (4.8-10.3) | 8.0 (5.5-11.0) |
Biochemical parameters | Â | Â |
CRP, mg/L | 89.0 (40.5-156.3) | 78.0 (29.8-235.3) |
Fibrinogen, mg/dL | 651.0 (489.3-752.5) | 594.0 (482.5-710.0) |
Hb, g/dL | 12.7 (11.9-13.8) | 12.1 (10.5-13.7) |
Prealbumin, g/dL | 0.14 (0.09-0.17) | 0.14 (0.10-0.18) |
GFR, mL/min | 54.9 (38.4-65.5) | 47.3 (31.6-56.4) |
Skeletal muscle evaluations | Â | Â |
GS*/body weight (kPa/kg) | 0.24 (0.11-0.43) | 0.44 (0.24-0.63) |
FR*/body weight (sec/kg) | 0.21 (0.03-0.54) | 0.37 (0.21-0.78) |
GW*/body weight (kPa × sec/kg) | 3.1 (0.1-8.2) | 7.5 (2.7-17.5) |
LBM (kg) | 24.0 (17.9-30.6) | 26.1 (24.9-30.3) |